Caribou Biosciences (CRBU) 2025 Conference June 04, 2025 09:20 AM ET Speaker0 Good morning everyone. I'm Farzin Hak, one of the biotech analysts in Maury Raycroft's team at Jefferies. It's my pleasure to introduce Rachel Hurwitz, CEO of Caribou Biosciences. This is a fireside chat format, so thank you for joining us today. Speaker1 Thanks, Farzin. Really appreciate it. Speaker0 So for those new to this story, can you provide a one minute overview of your platform and the programs? Speaker1 Yes, Caribou is u ...

BERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4th at 9:20 AM EDT. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at ...

Caribou Biosciences (CRBU) 2025 Conference May 13, 2025 05:35 PM ET Speaker0 Alright. So flipping straight into the next session, thank you for joining this session, with my name is Alex Stranahan. I'm senior biotech analyst at Bank of America covering Cariboo, and I'm pleased to be joined by Rachel Horowitz, president and CEO of Cariboo. Thanks for being here. Speaker1 Thanks for having us. We really appreciate it. Speaker0 Great. Well, we've got time for a mini fireside here, And and maybe just jumping in ...

Investors might want to bet on Caribou Biosciences, Inc. (CRBU) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 ______________________________________ Caribou Biosciences, Inc. ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ________________________________________ Delaware 001-40631 45-3728228 (Commission File Number) (IRS Employer Identification No.) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 ________________________________________ Caribou Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) ____________________________ ...

-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 -- BERKELEY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the first quarter 2025 and provided a business update for its lead oncolo ...

Caribou Biosciences, Inc. contacts: Investors: Amy Figueroa, CFA investor.relations@cariboubio.com Media: Peggy Vorwald, PhD media@cariboubio.com BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PD ...

-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 -- -- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 CaMMouflage r/r MM Phase 1 dose escalation dataset expected to includ ...

文章核心观点 - 分析Caribou Biosciences公司季度财报表现及股价走势，探讨未来发展并提及同行业TELA Bio公司业绩预期 [1][3][9] 公司业绩表现 - Caribou Biosciences本季度每股亏损0.39美元，优于Zacks共识预期的亏损0.40美元，去年同期每股亏损0.39美元，本季度财报盈利惊喜为2.50% [1] - 上一季度公司预期每股亏损0.44美元，实际亏损0.38美元，盈利惊喜为13.64% [1] - 过去四个季度，公司三次超出共识每股收益预期 [2] - 截至2024年12月季度，公司营收208万美元，未达Zacks共识预期18.23%，去年同期营收356万美元，过去四个季度仅一次超出共识营收预期 [2] 公司股价走势 - Caribou Biosciences自年初以来股价下跌约27%，而标准普尔500指数下跌1.9% [3] 公司未来展望 - 股票近期价格走势和未来盈利预期的可持续性主要取决于管理层在财报电话会议上的评论 [3] - 公司盈利前景可帮助投资者判断股票走向，包括当前对未来季度的共识盈利预期及预期变化 [4] - 盈利预测修正趋势与短期股价走势有强相关性，可通过Zacks Rank工具追踪 [5] - 财报发布前，Caribou Biosciences的预测修正趋势不利，当前Zacks Rank为4（卖出），预计近期股价表现逊于市场 [6] - 未来几天，未来季度和本财年的盈利预测变化值得关注，当前未来季度共识每股收益预期为亏损0.44美元，营收350万美元，本财年共识每股收益预期为亏损1.78美元，营收1140万美元 [7] 行业影响 - 行业前景会对股票表现产生重大影响，医疗 - 生物医学和遗传学行业目前在Zacks行业排名前26%，排名前50%的行业表现优于后50%超两倍 [8] 同行业公司情况 - 同行业TELA Bio公司尚未公布2024年12月季度业绩，预计3月20日发布 [9] - 该公司预计本季度每股亏损0.23美元，同比变化+56.6%，过去30天本季度共识每股收益预期未变 [9] - TELA Bio公司预计营收2330万美元，较去年同期增长37.1% [9]